title: Experimental treatment of stroke in spontaneously hypertensive rats by CD34+ and CD34- cord blood cells.
abstract: Human umbilical cord blood as a source of stem cells has recently been reported in experimental treatment of cerebral disorders. However, little is known about the nature of cells and cellular mechanisms leading to neurofunctional improvement. Here we investigated the potential of separated CD34(+) versus CD34(-) human umbilical cord blood cells (HUCBC) to promote functional recovery following stroke. The experiments were performed in spontaneously hypertensive (SH) rats, known for a risk profile comparable to stroke patients. After three weeks of behavioral training in the RotaRod and Beamwalk test arrays, stroke was induced by permanent middle cerebral artery occlusion (MCAO). For cell therapy, 1 x 10(6) cryopreserved cells were administered systemically between 8 and 10 hours after MCAO. The behavioral tests were performed together with a neurological severity score (mNSS) until day 29 to assess neurofunctional disabilities. Nearly complete functional remission was observed with both subpopulations CD34(+) as well as CD34(-) cells. To localize cells histologically, they were labeled with a fluorescence dye (CFSE) before injection. Again, after administration of CD34(+) as well as CD34(-) cells, CFSE labelled cells were found that accumulated in the border zone between the central necrosis of the ischemic lesion and functional brain tissue, thus indicating active attraction towards the lesion for both cell populations. Immunohistology with anti-CD68 and antibodies to human neuronal markers (NF-L, chromogranin) indicated an accumulation of human and rat monocytes in the border zone of the lesion while neuronal cells of human origin could not be detected in host brains.
authors.affiliation: Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Boltze
authors.forename: Ina
authors.initials: I
authors.lastname: Kowalski
authors.forename: Kathrin
authors.initials: K
authors.lastname: Geiger
authors.forename: Doreen
authors.initials: D
authors.lastname: Reich
authors.forename: Albrecht
authors.initials: A
authors.lastname: Gunther
authors.forename: Christian
authors.initials: C
authors.lastname: Buhrle
authors.forename: Dietmar
authors.initials: D
authors.lastname: Egger
authors.forename: Manja
authors.initials: M
authors.lastname: Kamprad
authors.forename: Frank
authors.initials: F
authors.lastname: Emmrich
references.citation: Eur Arch Psychiatry Clin Neurosci. 1993;242(4):179-83
references.pmid: 8461343
references.citation: Neurotox Res. 2003;5(5):355-68
references.pmid: 14715454
references.citation: Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5
references.pmid: 11121071
references.citation: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1968;259(2):211
references.pmid: 4232694
references.citation: Stroke. 1990 Apr;21(4):582-8
references.pmid: 1691534
references.citation: J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
references.pmid: 13502156
references.citation: Blood. 1991 Jun 15;77(12):2591-6
references.pmid: 1710512
references.citation: Lancet Neurol. 2002 Jun;1(2):92-100
references.pmid: 12849513
references.citation: Immunol Cell Biol. 1999 Dec;77(6):499-508
references.pmid: 10571670
references.citation: Brain Res. 1996 Nov 11;739(1-2):88-96
references.pmid: 8955928
references.citation: Exp Neurol. 2001 Sep;171(1):109-15
references.pmid: 11520125
references.citation: J Cell Mol Med. 2004 Jan-Mar;8(1):45-58
references.pmid: 15090260
references.citation: Stroke. 2001 Nov;32(11):2682-8
references.pmid: 11692034
references.citation: ILAR J. 2003;44(2):85-95
references.pmid: 12652003
references.citation: J Neurotrauma. 1994 Apr;11(2):187-96
references.pmid: 7932797
references.citation: Blood Coagul Fibrinolysis. 1999 Jul;10(5):277-84
references.pmid: 10456619
references.citation: J Clin Invest. 2004 Aug;114(3):330-8
references.pmid: 15286799
references.citation: Am J Med Sci. 1993 Nov;306(5):282-6
references.pmid: 8238081
references.citation: Neuroscience. 1999;91(2):519-25
references.pmid: 10366009
references.citation: Cell Transplant. 2002;11(3):275-81
references.pmid: 12075993
references.citation: J Cereb Blood Flow Metab. 1988 Aug;8(4):449-61
references.pmid: 2968987
references.citation: J Neurol Sci. 1996 May;137(2):69-78
references.pmid: 8782158
references.citation: J Cereb Blood Flow Metab. 2003 Jul;23(7):780-5
references.pmid: 12843782
references.citation: Blood. 2000 May 1;95(9):2813-20
references.pmid: 10779426
references.citation: Brain Res. 1995 Jun 5;682(1-2):182-8
references.pmid: 7552309
references.citation: J Cereb Blood Flow Metab. 1981;1(1):53-60
references.pmid: 7328138
references.citation: Stroke. 1984 Jul-Aug;15(4):755-8
references.pmid: 6464072
references.citation: J Hematother Stem Cell Res. 2003 Jun;12(3):255-70
references.pmid: 12857367
references.citation: Stroke. 2004 Oct;35(10):2385-9
references.pmid: 15345799
references.citation: Cell Transplant. 2002;11(3):261-4
references.pmid: 12075991
references.citation: Stroke. 1998 Oct;29(10):2189-95
references.pmid: 9756602
references.citation: Cytotherapy. 2002;4(2):109-18
references.pmid: 12006206
references.citation: J Neurosci Res. 2003 Aug 1;73(3):296-307
references.pmid: 12868063
references.citation: Ann Neurol. 2003 Jan;53(1):10-20
references.pmid: 12509843